APA (7th ed.) Citation

M, T., G, O., G, T., C, W., MCT, F., A, R., . . . A, D. (2019). A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease. Dove Medical Press.

Chicago Style (17th ed.) Citation

M, Taylor, Ousler G, Torkildsen G, Walshe C, Fyfe MCT, Rowley A, Webber S, Sheppard JD, and Duggal A. A Phase 2 Randomized, Double-masked, Placebo-controlled Study of Novel Nonsystemic Kinase Inhibitor TOP1630 for the Treatment of Dry Eye Disease. Dove Medical Press, 2019.

MLA (8th ed.) Citation

M, Taylor, et al. A Phase 2 Randomized, Double-masked, Placebo-controlled Study of Novel Nonsystemic Kinase Inhibitor TOP1630 for the Treatment of Dry Eye Disease. Dove Medical Press, 2019.